First Data on HIV-1 Resistance Mutations to Antiretroviral Drugs in Central African Republic

Moussa, Sandrine; Recordon-Pinson, Patrícia; Pelembi, Pulchérie; Gody, Jean-Chrysostome; Mbitikon, Olivia; Fikouma, Valentin; Mbay, Paulette; Fleury, Hervé

doi:10.1089/aid.2010.0091

Cited by 11 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,11,12,[15][16][17] In that context, the interest of laboratory monitoring, using immunological as well as virological markers, to prevent therapeutic failure in ARV-treated children, especially children less than 2 years old, 18 has still not been demonstrated by randomized clinical trial. In ARV-treated adults living in resource-limited settings, it is, however, currently well demonstrated that the lack of virological monitoring increases the risk of virological failure and the selection of ARVresistant viruses.…”

Section: Introductionmentioning

confidence: 99%

Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic

Charpentier

Gody

Mbitikon

et al. 2012

AIDS Research and Human Retroviruses

Self Cite

View full text Add to dashboard Cite

A total of 242 HIV-1-infected children were followed up at the Complexe Pédiatrique of Bangui, Central African Republic, including 165 receiving antiretroviral treatment in first- (n=150) or second-/third-line (n=15) regimens. They were prospectively included in a study, in 2009, to assess their virological status and prevalence of antiretroviral drug-resistance mutations in cases of virological failure, according to revised 2010 WHO criteria (e.g., HIV-1 RNA >3.7 log(10) copies/ml). Detectable plasma HIV-1 RNA was observed in 53% of children under first-line treatment, and virological failure was diagnosed in 40%, which was associated in 85% of cases with viruses harboring at least one drug-resistance mutation to nucleoside reverse transcriptase inhibitors (NRTI) or nonnucleoside reverse transcriptase inhibitors (NNRTI), and in 36% of cases with at least one major drug-resistance mutation to NRTI or NNRTI when excluding the M184V mutation. Overall, the proportion of children receiving a first-line regimen for a median of 18 months with virological failure associated with drug-resistance mutations, and thus eligible for a second-line treatment, was estimated at 34% of the whole cohort. In children under second-/third-line therapy, virological failure occurred in 47%, plus at least one major drug-resistance mutation to NRTI or NNRTI, though less commonly to protease inhibitors. Taken together, these findings argue in favor of the urgent need to improve distribution of pediatric antiretroviral drugs in the Central African Republic, to increase adherence by treated children, and to offer adequate HIV biological monitoring.

show abstract

Section: Introductionmentioning

confidence: 99%

Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic

Charpentier

Gody

Mbitikon

et al. 2012

AIDS Research and Human Retroviruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…These data confirm the high diversity of HIV-1, which reflects the different non-B subtypes/CRFs and the various drugs used, and do not provide evidence of new mutation profiles compared to subtype B. 14 Notwithstanding the difficult virological presentation, complicated by HBV coinfection, we designed an effective treatment combination that included RAL + DRV/r + TDF with the aid of precise molecular tools. Our patient presented a sustained immunological and virological response overcoming difficulties posed by a complex CXCR4-tropic CRF11-cpx virus.…”

mentioning

confidence: 58%

“…13 Our patient was from the Central African Republic. Initial data concerning HIV-1 resistance mutations to antiretroviral drugs in the Central African Republic were obtained by Moussa et al 14 In this study, they present sequence data of non-B HIV-1 isolates obtained in 2008-2009 from Central African patients failing a stavudine (d4T)/zidovudine (AZT)-3TC-nevirapine (NVP)/EFV regimen, together with two patients failing a regimen, including a protease inhibitor (indinavir, IDV). The resistance mutations observed are those that are expected in HIV-1 subtype B.…”

mentioning

confidence: 99%

Favorable Therapeutic Response with an Antiretroviral Salvage Regimen in an HIV-1-Positive Subject Infected with a CRF11-cpx Virus

TauPamela

Mancon

Mileto³

et al. 2014

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

HIV drug resistance still represents a crucial problem in antiretroviral therapy. We report a case of a naive patient, harboring a CRF11-cpx virus, which showed drug resistance mutations in the reverse transcriptase. A drug resistance genotyping test was performed for the pol (protease, reverse transcriptase, and integrase) and V3 regions. The initial clinical parameter results showed a 4 log level of HIV-RNA (12,090 cp/ml) and a very low CD4(+) cell count (35 cells/μl). We designed an initial highly active antiretroviral therapy (HAART) regimen including lamivudine (3TC)+abacavir (ABC)+booster ritonavir (DRV/r). The virus was highly resistant to all nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) except for ABC, tenofovir (TDF), and efavirenz (EFV) and was susceptible to all protease inhibitors (PIs) and integrase inhibitors (INIs). A salvage regimen including raltegravir (RAL)+DRV/r was started. Ten months later, the immunovirological status shows CD4(+) 142/μl and HIV-RNA <37 cp/ml. Our results demonstrate the effectiveness of a treatment combination that includes RAL+DRV/r in a patient infected with a complex X4-tropic CRF11-cpx virus.

show abstract

“…The complexity of CRF22_01A1 strains in Cameroon seemed to increase during the 2002–2010 period. The CRF22_01A1 strain has also been identified in Saudi Arabia 24, 25 , Equatorial Guinea 26, 27 , Central African patients 28 and USA 29 indicating that the CRF22 strain was spreading to different geographic regions.…”

Section: Discussionmentioning

confidence: 99%

CRF22_01A1 is Involved in the Emergence of New HIV-1 Recombinants in Cameroon

Zhao

Tang²,

Ragupathy³

et al. 2012

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Cameroon is a West African country where high genetic diversity of HIV-1 has been reported. The predominant CRF02_AG is involved in the emergence of more complex intersubtype recombinants. In this study, we sequenced the full-length genome of a novel unique recombinant form (URF) of HIV-1, 02CAMLT04 isolated in blood donors in urban Cameroon. Phylogenetic tree and bootscan analysis showed that 02CAMLT04 was complex and appeared to be a secondary recombinant derived from CRF02_AG and CRF22_01A1. The genomic composition of 02CAMLT04 strain showed that it is composed of three segments; twenty four percent of the genome is classified as CRF02_AG, spanning most of the envelope gene. The remaining seventy six percent of the genome is classified as CRF22_01A1. In addition, the sequence analysis of 13 full-length sequences from HIV-1 positive specimens received from Cameroon between 2002 and 2010 indicated that five specimens are pure CRF22_01A1 viruses, and six others have homology with CRF22_01A1 sequences in either gag, pol or env region where as 6% of strains contain portions of CRF22_01A1. Further study demonstrated that CRF22_01A1 is a primary prevalence strain co-circulating in Cameroon and is involved in complex intersubtype recombination events with subtypes (D or F), subsubtypes (A1 or F2) and CRFs (CRF01_AE or CRF02_AG). Our studies show that novel recombinants between CRF22_01A1 and other clades and recombinant forms may be emerging in Cameroon that could contribute to the future global diversity of HIV-1 in this region and world wide.

show abstract

First Data on HIV-1 Resistance Mutations to Antiretroviral Drugs in Central African Republic

Cited by 11 publications

References 6 publications

Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic

Virological Response and Resistance Profiles After 18 to 30 Months of First- or Second-/Third-Line Antiretroviral Treatment: A Cross-Sectional Evaluation in HIV Type 1-Infected Children Living in the Central African Republic

Favorable Therapeutic Response with an Antiretroviral Salvage Regimen in an HIV-1-Positive Subject Infected with a CRF11-cpx Virus

CRF22_01A1 is Involved in the Emergence of New HIV-1 Recombinants in Cameroon

Contact Info

Product

Resources

About